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ACh acetylcholine ADHD attention-deficit hyperactivity disorder ANOVA analysis of variance DAT dopamine transporter KO knockout 7-OH-DPAT 2-Dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene PHNO (+)-4-propyl-9-hydroxynaphthoxazine SB-277011A trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl) with high density in ventral striatum (Levant, 1997) and in lower concentration in other central nervous system sites. The receptor was cloned in 1990 (Sokoloff et al., 1990 ) and yet, after over twenty years and much investigation, the functional significance of this receptor has not been fully elucidated. D 3
receptors have been implicated in the control of drug dependence disorders, schizophrenia, and
Parkinson's disease (Micheli and Heidbreder, 2006; Joyce, 2004; Newman et al., 2012) . A number of selective ligands have been discovered but only the D 3 receptor-preferring agonist pramipexole is in clinical use for the treatment of Parkinson's disease and restless leg syndrome (Rascol et al., 2011; Scholz et al., 2011) . Pramipexole has been reported to have a range of selectivities of D 3 to D 2 receptors that range from none (Sautel et al., 1995) to about 100-fold (Millan et al., 2002) with both studies using iodosulpiride as a radioligand.
There have been a host of obstacles blocking the definitive identification of the functional significance of D 3 receptors. The relatively low density of these receptors and the lack of a range of selective pharmacological agents with high affinity and selectivity for D 3 receptors have been one set of limitations impeding success in this area. The lack of a method for identification of D 3 receptor activity in vivo has been another serious impediment. Although several methods have been proposed, many of these have been shown to be inconsistent when pharmacological data and data in D 3 receptor deficient mice are compared, or they are not consistent across the range of D 3 receptor antagonists studied (c.f., Perachon et al., 2000) . Recently two new in vivo assays have been proposed to define D 3 receptor blockade (Witkin et al., 2004; Collins et al., 2005) . JPET 198895 techniques have been established leveraging the discreet expression of dopamine D 3 receptor in lobules 9 and 10 of the cerebellum in vivo (Kiss, 2011) . We now report a new LC-MS/MS based method for defining the occupancy of compounds at D 3 receptors after systemic dosing that enables simultaneous assessment of D 2 receptor occupancy by using this regional specificity. This method uses a non-labeled tracer measured by LC/MS/MS, as previously reported for dopamine D 2 , NK 1 , 5HT 2A , and opioid receptors mu, kappa, and delta (Chernet et al., 2005; Barth et al., 2006; Need et al., 2007) . In the present study, LC/MS/MS receptor occupancy data were used to guide investigation of the in vivo activities of two D 3 receptor antagonists, SB-277011A and U99194. Specifically, we inquired as to whether blockade of D 3 receptors might impact acetylcholine (ACh) efflux and turnover, and whether these neurochemical effects were associated with the ability of the D 3 receptor antagonists affect the acquisition of behavior (learning) and to prevent memory deficits induced by the muscarinic receptor antagonist scopolamine, similar to effects produced by ADHD-treatment-related drugs. Since these neurochemical and behavioral data were aligned, we then showed that the D 3 receptor antagonists also significantly attenuated the hyperactivity of mice without dopamine transporters (DAT -/-mice), a model that detects the activity of drugs used in the therapeutic resolution of ADHD symptoms (Wickens et al., 2011; Fan et al., 2012) .
SB-277011A and U99194 are structurally-distinct antagonists of D 3 receptors with nanomolar affinities for the receptor. SB-277011A is 100-fold selective for D 3 receptors in its binding profile over D 2 receptors (Reavill et al., 2000) and U99194 displays only a 20-fold selectivity (Waters et al., 1993) .
Binding at these receptors however does not necessarily define in vivo selectivity and does not always even predict functional selectivity in vitro (Sautel et al., 1995) . Previous data have also suggested that some molecules might not function as selective D 3 receptor antagonists in vivo (Pearchon et al., 2000 ) . figure   1 . SB-277011A was dissolved in 25% beta-cyclodextrin; U99194, methylphenidate, and reboxetine were dissolved in water, and scopolamine was dissolved in 0.9% NaCl. For behavioral studies, compounds were injected i.p., or s.c., 30 min prior to testing (except for the object recognition experiments, see below). Compounds were dosed in a volume of 1 ml/kg for rats except in the behavioral acquisition studies (5 ml/kg) and 10 ml/kg (mice).
Receptor Occupancy. "Cold" epidepride was used as an occupancy tracer in the LC/MS/MSbased experiments and was administered at an intravenous dose of 3 ug/kg dissolved in sterile water (Chernet et al., 2005; Barth et al., 2006 Adult male Sprague-Dawley rats (HSD, Indianapolis, IN, USA) weighing 240-260 grams were housed 6 to a cage in a room using a 12-hour on/off lighting schedule (lights on at 6 AM). Room temperature was maintained at 21 ± 3 °C. Animals had ad libitum access to food and water and were permitted at least 2 days after arrival at our site to adapt to housing conditions before testing.
Dopamine D 3 receptor occupancy in vivo.
Tracer dose (3μg/kg) and survival interval (40 min)
were optimized for epidepride to generate detectable and quantifiable in vivo levels in lateral cerebellum, lobules 9 and 10 of the cerebellum, and dorsal striatum by liquid chromatography coupled to tandem mass spectrometry (Barth et al., 2006) . Tissue levels of epidepride in the lateral cerebellum represent nonspecific binding, those in lobules 9 and 10 of the cerebellum represent total binding for D 3
receptor occupancy measurements, and epidepride levels in the dorsal striatum represent the total This article has not been copyedited and formatted. The final version may differ from this version. Epidepride concentration measurements were made using a liquid chromatograph (HPLC, Agilent Technologies model 1100, Wilmington, DE, USA) with triple quadrapole mass spectral detection. The HPLC system employed a C18 column (ZORBAX Eclipse, 2.1 x 50mm, 3.5 micron particle size, Agilent) with an aqueous mobile phase consisting of 23% acetonitrile with 0.1% formic acid. Epidepride was quantified after elution from the HPLC column using an API 3000 triple quad mass spectrometer (Applied Biosystems, Foster City, CA, USA) in positive electrospray mode using MRM methods to monitor the transition from precursor to fragment ions with mass to charge ratios of 419.2 and 112.1 respectively. Chromatographic assays were calibrated using a standard curve generated by extracting a series of brain tissue samples from non-treated animals to which known quantities of epidepride had been added.
Receptor occupancy calculation. Receptor occupancy calculations were made for each animal employing the widely used ratio method (Farde et al., 1988; Kapur et al., 1999; Wadenberg et al., 2000) and represents the average ratio of epidepride levels measured in the striatum or lobules 9 and 10 to that measured in the lateral cerebellum for the vehicle-pretreated group.
In vivo microdialysis in rats. All studies were performed according to the guidelines set forth by the Paxinos and Watson (1996) . Twenty-four hours before testing, a 4 mm concentric microdialysis probe (BAS, model BR-4) was inserted through the guide cannula. The actual location of the probes was verified histologically at the end of the experiment.
Acetylcholine (ACh) measurements. ACh determination in dialysates from the different brain regions was performed as described previously (Shirazi-Southall et al., 2002; Tzavara et al., 2006a Data analysis. Data were expressed as multifold change from baseline, which is the average of the five basal values before any manipulation and were analyzed either with one-way, i.e. treatment (between subjects variable), two-way, i.e. treatment (between subjects variable) X time (within subjects variable), or three-way (treatment 1 X treatment 2 X time) ANOVA followed by Duncan's test. The effects of each of the drugs are presented both over a course of time every 15 min after the injection of the drug as well as overall average effects during the 3-hour observation period after the injection of the drug (index of area under curve); data analyzed with one-way ANOVA followed by Bonferroni's test).
Acetylcholine and choline tissue levels in rats.
Male Sprague-Dawley rats (175-225 g, purchased from Harlan Sprague-Dawley, Indianapolis, IN) were used for the experiments Rats were injected i.p. with the compounds under study and 30 min later they were decapitated with a guillotine and their brains quickly removed and placed on an ice cold plate. The cortex, hippocampus and striatum were dissected free hand on ice, weighed and stored at -80°C until they were assayed. Tissue preparation, extraction and measurement of ACh and choline were made essentially as reported previously (Bymaster et al., 1985) . Results for ACh and choline are expressed as nmol/g tissue from which the ratio of choline/ACh (turnover index) are calculated; all data from each brain region are analyzed with one-way ANOVA followed by the Tukey's LSD test for multiple comparisons.
Acquisition of behavior.
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Male Sprague Dawley rats (Harlan Sprague Dawley) weighing 40-50 g upon arrival were randomly placed 5 per cage with free access to food and water. Each rat was studied in only one experiment.
The shuttle boxes (Med Assoc.), 21 cm on each side separated by a guillotine door, were equipped with metal grid floors through which electrical stimuli could be delivered and scrambled across the grids (Med Assoc.).
The experimental protocol was a modification of that used previously (Fox et al., 2003) . After dosing, the rats were put into individual cages for the duration of pre-treatment interval after which they were placed into the right side of shuttle box. Ten seconds later the light was turned on and the door opened. If the animal did not cross over into the left hand side of the shuttle box within 180 seconds, the trial ended the door closed; 10 sec later the door was re-opened and the next trial began. When the animal crossed to the other side of the box, the timer is stopped, the door closed and 7 sec later the grid floor was electrified (0.2 mA, 1 sec). After current delivery, the rat was manually removed and placed back into the right hand side of the shuttle box and the procedure was repeated until 5 trials were completed. All events and timers were controlled by a computer operating Med Associates software.
The latency to cross over to the left hand side was recorded for each of the 5 trials. Trial latencies were analyzed using ANOVA followed by Dunnett's test. Comparison of vehicle to drug treatments across trials was evaluated by two-tailed, two-way ANOVA. For this analysis, trials 3-5 were used. Probabilities < 0.05 were considered significant. designated A. The rat was allowed to explore for 2 min and the time interacting with the objects (sniffing, gnawing and behavior oriented to an object) was recorded. After 3 minutes the rat was returned to the observation box for the test trial. The test box contained a familiar object (object A) and a novel (object B) object.
A separate study was conducted in which the ability of SB-297011A to augment the protective effects of reboxetine against scopolamine degredation was evaluated. In this study, a non-effective dose of reboxetine (3 mg/kg) was given alone or in combination with with low, non-effective doses of SB-297011A (1 or 3 mg/kg). In an additional study, rats were studied for effects of SB-2977011A in the absence of scopolamine. The study was conducted as above with the exception that the interval between exploration periods 1 and 2 was 3 hr instead of 3 min.
The amount of time spent interacting with each object during the 2-min test was recorded.
Results are expressed as the percentage of time spent interacting with the new object B and were analyzed with a one-way ANOVA. The ability of compounds to produce effects statistically differentiated from that of either vehicle, scopolamine, or reboxetine + scopolamine were evaluated by post-hoc Dunnett's tests.
Dopamine transporter knockout mice.
Breeding, genotyping and maintenance of the mice. DAT KO mice were obtained by homologous recombination (Giros et al., 1996) and maintained on two inbred genetic backgrounds: fig. 3) . At this dose level, the effect of SB-277011A on cortical ACh levels was more pronounced than the effect of U99194, when the data were expressed and analyzed as overall average effects (inserts in figure 3 ), which was due to the fact that SB-277011A exerted a longer-lasting effect on ACh compared to the effect of U99194 ( fig. 3 ).
To further explore the effects of these D 3 receptor antagonists on cholinergic neurochemistry, tissue levels of ACh and choline were examined. Figure 3 shows, in accord with the increases in extracellular levels of ACh in the medial prefrontal cortex, corresponding significant and dosedependent decreases in tissue levels of ACh in the hippocampus, the cortex, and the striatum after SB-277011A administration. SB-277011A also increased choline levels in the hippocampus and the striatum at 60 mg/kg (fig. 4) . The SB-277011A-induced increases in the ratio choline/ACh were found significant This article has not been copyedited and formatted. The final version may differ from this version. in the hippocampus and cortex at 30 and 60 mg/kg, and in the striatum at 60 mg/kg. Generally, comparable effects were observed after dosing with U99194 at doses of 30 and 60 mg/kg, although it did not significantly affect choline in any of the brain regions studied or the ratio of choline/ACh in the striatum ( fig. 5) .
Acquisition of behavior. Drugs were evaluated for their ability to enhance the acquisition of behavior of rats. Under the conditions studied, the performance of the rats increased over successive trails (F 4,49 = 6.7, p < 0.001) ( fig. 6 ). Post-hoc Dunnett's test revealed that performance on trials 3, 4, and 5 were significantly better than on trial (p < 0.05).
Methylphenidate significantly enhanced the acquisition of behavior (F 2,69 = 7.5, p < 0.05). For reboxetine, a trend toward significance was achieved (F 2,81 = 5.9, p = 0.07). Analysis of the 10 mg/kg dose of reboxetine relative to vehicle revealed a significant enhancement of behavioral acquisition (F 1,54 = 7.6, p < 0.05). A similar trend for enhancement was seen with U99194 (F 2,63 = 5.9, p = 0.08); when the 30 mg/kg dose of U99194 was compared to vehicle, a significant augmentation in acquisition of behavior was observed (F 1,45 = 7.6, p < 0.05). SB-277011A did not significantly enhance behavioral acquisition (F 2,66 = 1.8, p = 0.5).
Object recognition. Scopolamine produced a significant degradation in performance in the object recognition task ( fig. 7 ). Both SB-277011A and U99194 prevented these effects of scopolamine at both 10 and 30 mg/kg. Reboxetine was also effective in preventing scopolamine-induced performance effects at 10 and 30 but not at 3 mg/kg ( fig. 7 ).
SB-277011A was also evaluated for its ability to enhance novel object recognition on its own was also evaluated. In this experiment, a 3 hr delay instead of 3 min was imposed before presentation of the novel object. Under these conditions, performance compared to the 3 min condition was degraded to a level like that imposed by scopolamine. The percent time exploring the novel object was vehicle = trend for an effect with 10 mg/kg, these effects were not significantly different than vehicle control values.
In order to evaluate the potential for D 3 receptor blockade to enhance the efficacy of reboxetine, lower doses of SB-277011A were tested. Neither 1 nor 3 mg/kg SB-277011A significantly prevented the effects of scopolamine ( fig. 8 ). When these doses of SB-277011A were tested against a noneffective dose of reboxetine (3 mg/kg), SB-277011A dose-dependently augmented the protective effects of reboxetine ( fig. 8 ).
Dopamine transporter null mice (DAT -/-).
DAT -/-mice had markedly enhanced basal locomotor activity levels than age-matched wild-type (WT controls) ( fig. 9 ). d-Amphetamine (3 mg/kg, i.p.) significantly decreased activity levels in the KO mice and significantly increased activity of WT mice (two way ANOVA shows significant interaction between genotype and treatment, F 1,31 =52.9; p<0.0001). In contrast to the effects of d-amphetamine, SB-277011A (3-30 mg/kg, i.p.) (two-way ANOVA shows significant interaction between genotype and treatment with F 3,39 =13; p<0.0001) and U99194 (30 and 60 mg/kg, i.p.) (two-way ANOVA shows significant interaction between genotype and treatment with F 3,34 =3.02; p<0.05) significantly attenuated the hyperactivity of DAT KO mice without significantly altering the activity of WT mice. Reboxetine (an analogue of atomoxetine, a non-stimulant drug with proven efficacy in patients with ADHD) was also studied. Under these conditions, reboxetine significantly decreased locomotor hyperactivity of the DAT KO mice at doses of 5 and 10 mg/kg, i.p.
without affecting levels of activity of WT mice (two way ANOVA shows significant interaction between genotype and treatment of F 2,61 =5.1; p<0.001).
This article has not been copyedited and formatted. The final version may differ from this version. Using these methods, we determined that both SB-277011A and U99194 can achieve significant occupancy of D 3 receptors in rat brain upon systemic administration. receptors by SB-277011A was <5%, whereas the occupancy of D 2 receptors by U99194 was about 20%.
The ability to measure occupancy of receptors in vivo is key to defining the relationship of target engagement to biological effect. The receptor occupancy data on these molecules extends the limited findings in the published literature. The occupancy of D 3 receptors in vivo by SB-277011A is thus consistent with one dose-response finding reported with an agonist radioligand (Rabiner et al., 2009 ).
We cannot find any data in the literature on the occupancy of dopamine receptors in vivo by U99194.
Our current data on U99194 is a key testament to the need for such in vivo target engagement bioassays in assessing the value of research tools. It is generally appreciated that high in vitro potency or selectivity do not necessarily translate in vivo (e.g., Pearchon et al., 2000) . Although SB-277011A is 100-fold selective for D 3 receptors in its binding profile over D 2 receptors (Reavill et al., 2000) , U99194
is only 20-fold selectivity (Waters et al., 1993) , suggesting that the compound at higher doses will cross over significantly to D 2 receptors in vivo. Indeed, it is often assumed that low potency or selectivity in vitro translates to poor potency or selectivity in vivo. However, the high occupancy of D 3 receptors by U99194 at 60 mg/kg (81%) and the ability of U99194 to block a D 3 -mediated behavioral effect (Collins et al., 2005) indicate that the low selectivity of this molecule in vitro is less of a liability than previously observed with reboxetine, an analog of the ADHD-treatment drug atomoxetine, which also prevents scopolamine-induced deficits (Tzavara et al., 2006a) . SB-277011A also enhanced the effects of reboxetine in this task. In addition, U99194 enhanced the learning of rats in a 5-trial shuttle box procedure also sensitive to the ADHD drug methylphenidate and to reboxetine (present study) as well as to other pro-cognitive mechanisms (e.g., Fox et al., 2003) . These findings implicate D 3 receptors as negative regulators of attentional processing and are consistent with a literature of cognitive improvements with D 3 receptor antagonism (Laszy et al., 2005; Braszko et al., 2010; Micale et al., 2010) that oppose cognitive deficits impacted by D 3 receptor agonists (Smith et al., 1999) . A polymorphism of the D 3 receptor has been associated with the cognitive impairments in schizophrenia (Szekeres et al., This article has not been copyedited and formatted. The final version may differ from this version. 2004; Bombin et al., 2008) and D 3 receptor blockade might be associated with some of the beneficial cognitive impacting effects of atypical antipsychotic agents and of selective D 3 receptor antagonists (Lacroix et al., 2003; Lumme et al., 2007; Millan and Brocco, 2008) . However, clinical data also have suggested cognitive benefit from the anti-Parkinson D 3/2 receptor agonist pramipexole (Levin et al., 2009) .
In vivo models for predicted drug efficacy in ADHD are imperfect. However, although no disease models exist, multiple in vivo readouts do detect effects of drugs used in ADHD therapeutics such as methylphenidate, d-amphetamine, and atomoxetine (Wickens et al., 2011) . In the present study, effects on cognitive aspects of the disorder including attentional deficits were studied in rats, where methylphenidate and the atomoxetine analog, reboxetine, were used as positive controls. Modeling of the hyperactivity symptoms of ADHD has utilized the dopamine transporter (DAT) -/-mouse. Indeed, several genetic studies show an association between a polymorphism in the non-coding regions of the DAT gene and ADHD, suggesting that DAT-mediated processes could significantly contribute to the pathogenesis of this disorder. In the DAT KO mice, a five-fold increase in extracellular DA in the brain is associated with dramatic hyperactivity. This hyperactivity, paradoxically, is inhibited by psychostimulants, like amphetamine and methylphenidate, thereby providing a simple model in which the effects of ADHD pharmacological agents can be assessed (Gainetdinov and Caron, 2003) .
In the present study, we showed that the ADHD drugs d-amphetamine and reboxetine decreased the profound hyperactivity of DAT -/-mice. This dampening effect was also observed with two 
